Mercury Systems (NASDAQ:MRCY – Get Free Report) and Mainz Biomed (NASDAQ:MYNZ – Get Free Report) are both industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.
Institutional and Insider Ownership
96.0% of Mercury Systems shares are held by institutional investors. 1.0% of Mercury Systems shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Mercury Systems has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Mercury Systems and Mainz Biomed, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mercury Systems | 2 | 3 | 7 | 1 | 2.54 |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
Mercury Systems currently has a consensus target price of $108.10, suggesting a potential upside of 38.36%. Given Mercury Systems’ stronger consensus rating and higher probable upside, equities analysts clearly believe Mercury Systems is more favorable than Mainz Biomed.
Profitability
This table compares Mercury Systems and Mainz Biomed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mercury Systems | -0.40% | 2.52% | 1.58% |
| Mainz Biomed | N/A | N/A | N/A |
Earnings & Valuation
This table compares Mercury Systems and Mainz Biomed”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mercury Systems | $983.62 million | 4.84 | -$29.67 million | ($0.08) | -976.62 |
| Mainz Biomed | $659,935.00 | 8.69 | -$21.65 million | ($65.60) | -0.01 |
Mainz Biomed has lower revenue, but higher earnings than Mercury Systems. Mercury Systems is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Summary
Mercury Systems beats Mainz Biomed on 10 of the 15 factors compared between the two stocks.
About Mercury Systems
Mercury Systems, Inc. develops and supplies secure processing systems and subsystems for the aerospace and defense industries. Its products include embedded computing, signal processing, radio-frequency and microwave components, and other technologies used to process and manage critical data. The company’s technologies support applications such as radar, electronic warfare, communications, avionics, and command-and-control systems. Mercury works with defense contractors and government customers, providing components and systems designed for use in demanding environments.
About Mainz Biomed
Mainz Biomed is a molecular diagnostics company focused on developing tests for the early detection of cancer. The company is headquartered in Mainz, Germany, and serves markets in Europe and other regions. Its lead product, ColoAlert, is a noninvasive, stool-based screening test designed to detect colorectal cancer and precancerous lesions. The test uses molecular analysis alongside a fecal immunochemical test (FIT). Mainz Biomed is also developing PancAlert, a diagnostic test intended to support the early detection of pancreatic cancer.
Receive News & Ratings for Mercury Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mercury Systems and related companies with MarketBeat.com's FREE daily email newsletter.
